Subscribe Us

header ads

Recents

header ads

KRAS Inhibitors Market Size, Growth, Demands Outlook and Forecasts to 2032

According to the research report, the global KRAS inhibitors market size is expected to touch USD 165.63 million by 2032, from USD 102.36 million in 2022, growing with a significant CAGR of 4.93% from 2023 to 2032.

KRAS Inhibitors Market Size 2023 To 2032

The KRAS inhibitors report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global KRAS inhibitors in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global KRAS inhibitors market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global KRAS inhibitors during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/3035

This study covers a detailed segmentation of the global KRAS inhibitors market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global KRAS inhibitors market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

  • Amgen
  • Boehringer Ingelheim
  • BridgeBio Pharma
  • Erasca
  • Innovent Biologics, Inc.
  • Incyte
  • Mirati Therapeutics
  • Novartis
  • Jemincare
  • Cardiff Oncology, Inc.

Market Segmentation

By Cancer Type

  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Others

By End-Use

  • Clinic Laboratories
  • Cancer Diagnostic Centers
  • Hospitals
  • Cancer Research Institutes
  • Academic Institutions
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Research Methodology

The research methodology adopted by analysts for compiling the global KRAS inhibitors report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global KRAS inhibitors market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on KRAS Inhibitors Market 

5.1. COVID-19 Landscape: KRAS Inhibitors Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global KRAS Inhibitors Market, By Cancer Type

8.1. KRAS Inhibitors Market Revenue and Volume, by Cancer Type, 2023-2032

8.1.1. Lung Cancer

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Pancreatic Cancer

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Colorectal Cancer

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Others

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global KRAS Inhibitors Market, By End-Use

9.1. KRAS Inhibitors Market Revenue and Volume, by End-Use, 2023-2032

9.1.1. Clinic Laboratories

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Cancer Diagnostic Centers

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Hospitals

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

9.1.4. Cancer Research Institutes

9.1.4.1. Market Revenue and Volume Forecast (2020-2032)

9.1.5. Academic Institutions

9.1.5.1. Market Revenue and Volume Forecast (2020-2032)

9.1.6. Others

9.1.6.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global KRAS Inhibitors Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.1.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.1.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.1.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.2.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.2.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.2.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.2.5.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.2.6.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.3.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.3.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.3.5.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.3.6.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.4.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.4.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.4.5.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.4.6.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.5.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.5.3.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Cancer Type (2020-2032)

10.5.4.2. Market Revenue and Volume Forecast, by End-Use (2020-2032)

Chapter 11. Company Profiles

11.1. Amgen

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Boehringer Ingelheim

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. BridgeBio Pharma

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Erasca

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Innovent Biologics, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Incyte

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Mirati Therapeutics

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Novartis

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Jemincare

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Cardiff Oncology, Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com

Post a Comment

0 Comments